Novartis ($NVS) pulls Zometa app after study disappoints

Novartis ($NVS) has hit a big obstacle in its push to expand use of the bone drug Zometa. A new study showed that the drug didn't keep breast cancer at bay or prolong patients' lives, almost exactly the opposite of the results observers--and the company--were expecting. An earlier, smaller study had indicated that Zometa helped prevent recurrence, and the company was so confident of this new data that it had already asked FDA for a breast cancer indication.

Now, the Swiss drugmaker will pull its applications for the new use--to prevent breast cancer relapse--in Europe and the U.S. The company is deciding whether to pursue a new trial to support a new application for approval. That's in part because the study did show a survival benefit in a subset of patients, namely women who were five years post-menopause.

The new Zometa indication was part of Novartis' patent-cliff strategy: The drug loses protection in 2013, but the new use could have won three additional years of exclusivity. And some analysts were touting the breast-cancer indication as a $1 billion sales booster by 2015. "This will be a surprise to most people," the lead investigator, Dr. Robert Coleman, told Reuters. "I think most people expected this to be a positive trial, but it isn't."

- see the Bloomberg news
- get more from Reuters

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.